Congenital adrenal hyperplasia- Pipeline Insight, 2026

DelveInsight’s, “Congenital-adrenal-hyperplasia- Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Congenital-adrenal-hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Congenital-adrenal-hyperplasia: Understanding

Congenital-adrenal-hyperplasia: Overview

Congenital adrenal hyperplasia (CAH) is a group of inherited endocrine disorders characterized by defects in enzymes required for cortisol biosynthesis in the adrenal cortex, most commonly due to mutations in the 21-hydroxylase enzyme. CAH is typically inherited in an autosomal recessive pattern and leads to impaired cortisol production, with or without aldosterone deficiency, and excess androgen synthesis.

The condition is broadly classified into two main types: classic CAH (which includes salt-wasting and simple virilizing forms and presents in infancy or early childhood) and non-classic CAH (a milder, late-onset form presenting in adolescence or adulthood).

The cause of CAH is genetic mutations in steroidogenic enzymes, most commonly CYP21A2, leading to enzyme deficiency. The pathophysiology involves reduced cortisol production, which triggers increased secretion of adrenocorticotropic hormone (ACTH) via negative feedback, resulting in adrenal hyperplasia and overproduction of androgenic steroids; in severe cases, aldosterone deficiency can lead to salt wasting, dehydration, and electrolyte imbalance.

Diagnosis is made through newborn screening (measurement of 17-hydroxyprogesterone levels), serum hormone analysis, ACTH stimulation tests, and genetic testing to confirm enzyme defects. Treatment focuses on lifelong hormone replacement therapy, including glucocorticoids to replace cortisol and suppress excess ACTH, and in some cases mineralocorticoids to manage aldosterone deficiency, along with salt supplementation in infants; additional management may include surgical correction of genital abnormalities and monitoring for growth and metabolic complications.

""Congenital-adrenal-hyperplasia - Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital-adrenal-hyperplasia pipeline landscape is provided which includes the disease overview and Congenital-adrenal-hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Congenital-adrenal-hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital-adrenal-hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Congenital-adrenal-hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Congenital-adrenal-hyperplasia.

Congenital-adrenal-hyperplasia Emerging Drugs Chapters

This segment of the Congenital-adrenal-hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Congenital-adrenal-hyperplasia Emerging Drugs

• Atumelnant: Crinetics Pharmaceuticals

Atumelnant (also known as CRN04894), developed by the Crinetics Pharmaceuticals, is an investigational, once-daily oral small-molecule adrenocorticotropic hormone (ACTH) receptor antagonist being developed for endocrine disorders, including congenital adrenal hyperplasia (CAH). Atumelnant works by selectively blocking the melanocortin type 2 receptor (MC2R)—the ACTH receptor located in the adrenal cortex—thereby inhibiting ACTH signaling and reducing the overproduction of adrenal androgens and steroid precursors that drive CAH pathology.The drug is specifically being developed for classic congenital adrenal hyperplasia, a genetic disorder characterized by cortisol deficiency and excess ACTH stimulation leading to androgen overproduction. By targeting the root cause (ACTH-driven adrenal stimulation), atumelnant aims to normalize hormone levels and reduce reliance on high-dose glucocorticoid therapy, which is the current standard of care. Atumelnant has received FDA Orphan Drug Designation (ODD) for the treatment of congenital adrenal hyperplasia. Atumelnant is currently in late-stage clinical development (Phase III). Additionally, the company has initiated Phase 2/3 pediatric trials, further confirming its advanced development status.

• NBIP-1435: Neurocrine Biosciences

NBIP-1435, developed by Neurocrine Biosciences, is an investigational peptide-based corticotropin-releasing factor type 1 (CRF1) receptor antagonist that is currently part of the company’s pipeline for congenital adrenal hyperplasia (CAH). NBIP-1435 works by blocking CRF1 receptors, which are upstream regulators of the hypothalamic–pituitary–adrenal (HPA) axis. By inhibiting CRF1 signaling, the drug is expected to reduce adrenocorticotropic hormone (ACTH) release, thereby decreasing excessive adrenal stimulation and lowering androgen overproduction, which is the key driver of CAH pathology. The drug is specifically being developed for classic congenital adrenal hyperplasia, where dysregulated ACTH signaling leads to cortisol deficiency and androgen excess. NBIP-1435 is currently in Phase I clinical trials.

Further product details are provided in the report……..

Congenital-adrenal-hyperplasia: Therapeutic Assessment

This segment of the report provides insights about the different Congenital-adrenal-hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Congenital-adrenal-hyperplasia
• There are approx. 5+ key companies which are developing the therapies Congenital-adrenal-hyperplasia. The companies which have their Congenital-adrenal-hyperplasia drug candidates in the most advanced stage, i.e. Phase III include, Crinetics Pharmaceuticals, and others.
• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Congenital-adrenal-hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Congenital-adrenal-hyperplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Congenital-adrenal-hyperplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital-adrenal-hyperplasia drugs.

Congenital-adrenal-hyperplasia Report Insights

• Congenital-adrenal-hyperplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Congenital-adrenal-hyperplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Congenital-adrenal-hyperplasia drugs?
• How many Congenital-adrenal-hyperplasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital-adrenal-hyperplasia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Congenital-adrenal-hyperplasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Congenital-adrenal-hyperplasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Crinetics Pharmaceuticals Inc.
• Neurocrine Biosciences

Key Products

• Atumelnant
• NBIP'1435

Show more